Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib plus HDACi in HR+/HER2- advanced breast cancer
NCT06556862Phase 2Not yet recruiting
- Sponsor
- The Fifth Medical Center of the PLA General Hospital
- Start
- Oct 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dalpiciclib in breast cancer, sponsored by The Fifth Medical Center of the PLA General Hospital. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06556862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06556862.